Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM

Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM

Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

Efficacy and Safety of Extended Treatment with Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Incidence and Impact of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Trials

Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis

Aficamten vs Metoprolol as Monotherapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

Toward a Quantitative Understanding of Aficamten Clinical Pharmacology: Population Pharmacokinetic Modeling

Participant, Site Personnel and Sponsor Perspectives on Decentralized Trial Features in COURAGE-ALS: a Randomized Clinical Trial